GeneDx (NASDAQ:WGS) Director Keith Meister Buys 140,000 Shares

GeneDx Holdings Corp. (NASDAQ:WGS) Director Keith Meister purchased 140,000 shares of the company’s stock in a transaction on Thursday, May 14th. The shares were purchased at an average cost of $39.39 per share, for a total transaction of $5,514,600.00. Following the completion of the transaction, the director directly owned 4,738,297 shares of the company’s stock, valued at approximately $186,641,518.83. This represents a 3.04% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

GeneDx Stock Performance

NASDAQ WGS opened at $40.75 on Friday. The company has a current ratio of 3.09, a quick ratio of 2.95 and a debt-to-equity ratio of 0.38. The firm’s fifty day moving average price is $64.01 and its two-hundred day moving average price is $102.00. GeneDx Holdings Corp. has a 1 year low of $32.21 and a 1 year high of $170.87. The firm has a market capitalization of $1.21 billion, a P/E ratio of -15.21 and a beta of 2.06.

GeneDx (NASDAQ:WGS) last posted its quarterly earnings results on Monday, May 4th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.22). GeneDx had a positive return on equity of 9.15% and a negative net margin of 17.58%.The firm had revenue of $102.25 million for the quarter, compared to the consensus estimate of $112.46 million. During the same period last year, the company posted ($0.23) earnings per share. As a group, research analysts anticipate that GeneDx Holdings Corp. will post -1 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on WGS shares. Guggenheim dropped their price objective on shares of GeneDx from $100.00 to $70.00 and set a “buy” rating on the stock in a research report on Tuesday, May 5th. Weiss Ratings reissued a “sell (d)” rating on shares of GeneDx in a research report on Wednesday, January 21st. Canaccord Genuity Group set a $75.00 price objective on shares of GeneDx and gave the stock a “buy” rating in a research note on Tuesday, May 5th. Piper Sandler reiterated an “overweight” rating and set a $130.00 price objective (down from $160.00) on shares of GeneDx in a research note on Tuesday, February 24th. Finally, Jefferies Financial Group set a $150.00 price objective on shares of GeneDx in a research note on Monday, February 23rd. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $96.43.

Institutional Investors Weigh In On GeneDx

A number of hedge funds have recently made changes to their positions in WGS. Royal Bank of Canada raised its holdings in GeneDx by 30.2% in the 1st quarter. Royal Bank of Canada now owns 29,479 shares of the company’s stock valued at $2,611,000 after buying an additional 6,840 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in GeneDx by 6.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,641 shares of the company’s stock valued at $677,000 after buying an additional 453 shares during the last quarter. NewEdge Advisors LLC raised its holdings in GeneDx by 270,700.0% in the 1st quarter. NewEdge Advisors LLC now owns 2,708 shares of the company’s stock valued at $240,000 after buying an additional 2,707 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in GeneDx by 67.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 28,224 shares of the company’s stock valued at $2,500,000 after buying an additional 11,375 shares during the last quarter. Finally, Cetera Investment Advisers bought a new position in GeneDx in the 2nd quarter valued at approximately $249,000. 61.72% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting GeneDx

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Director Keith A. Meister kept buying shares, including 165,000 shares on May 13, 140,000 shares on May 14, and 46,273 shares on May 15, signaling strong insider confidence in GeneDx’s outlook and helping support the stock. Insider trade filing
• Neutral Sentiment: GeneDx received an average brokerage recommendation of “Moderate Buy,” suggesting Wall Street still sees upside despite the recent volatility. Brokerage recommendation article
• Negative Sentiment: A legal update from Pomerantz LLP said it is investigating claims on behalf of GeneDx investors, adding overhang from possible shareholder litigation after the company’s recent results. Pomerantz investigation article
• Negative Sentiment: Another law firm, Levi & Korsinsky, announced a securities investigation tied to GeneDx’s Q1 revenue miss and reduced full-year guidance, reinforcing concerns that the post-earnings selloff may not be over. Levi & Korsinsky investigation article
• Negative Sentiment: An analyst note cut GeneDx’s price target sharply to $98.94, highlighting a more cautious view after the company’s disappointing quarter. Price target cut article

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.